European Journal of Pediatrics

, Volume 173, Issue 2, pp 223–228 | Cite as

Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis

  • Pauline De BruyneEmail author
  • Ann De Guchtenaere
  • Charlotte Van Herzeele
  • Ann Raes
  • Jo Dehoorne
  • Piet Hoebeke
  • Erik Van Laecke
  • Johan Vande Walle
Original Article


Desmopressin 120 μg oral lyophilisate and 200 μg tablet are considered bioequivalent, based on extrapolation of studies in a limited number of adults and on one dose-finding study of desmopressin oral lyophilisate in children. However, no comparative pharmacokinetic study in children was executed confirming this statement. No data are available on the influence of food intake on the bioavailability of desmopressin tablet in a pediatric setting, although studies in adults have documented that food intake results in a significantly lower desmopressin plasma concentration. In this study, we analyzed plasma concentrations of desmopressin oral lyophilisate and tablet with concomitant food intake. Twenty-three children with monosymptomatic nocturnal enuresis (mean age, 12.7 years) were recruited. Two tests were performed on two separate days in identical conditions with a standardized food and fluid intake. Desmopressin was administered as desmopressin tablet or desmopressin oral lyophilisate immediately after a meal. Desmopressin plasma concentration was measured at 1 h, 2 h, and 6 h postdosing. No significant difference in plasma concentration of 120 μg desmopressin oral lyophilisate and 200 μg tablet was demonstrated, even with concomitant food intake. A significant difference in variability was found, identifying a smaller variance for desmopressin oral lyophilisate plasma concentrations at all time points. This study demonstrates comparable plasma levels for desmopressin oral lyophilisate, despite the lower dose. The dosage for desmopressin oral lyophilisate is more predictable due to the significantly smaller variance. Therefore, desmopressin oral lyophilisate seems more suitable, especially in the younger age group for which time interval between dinner and drug administration is limited.


Pharmacokinetics Desmopressin Monosymptomatic nocturnal enuresis Children 



1-deamino-8-d-Arginine vasopressin


European Medicines Agency


International Conference on Harmonization


Liquid chromatography coupled with tandem mass spectrometry


Pediatric investigational plan






Pediatric use marketing authorization



This study was investigator-driven and was in part supported by an unrestricted grant from Ferring International. Pauline De Bruyne has received an independant grant for Strategic Basic Research of the Agency for Innovation by Science and Technology in Flanders (IWT).


  1. 1.
    (EMA), E. M. A. (2000). Note for guidance on the investigation of bioavailability and bioequivalence Google Scholar
  2. 2.
    Agency, E. M. (2006). REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 december 2006. Retrieved January 29, 2013, from Accessed 29 Jan 2013
  3. 3.
    Antosova Z, Mackova M, Kral V, Macek T (2009) Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 27(11):628–635PubMedCrossRefGoogle Scholar
  4. 4.
    Baylis PH, Cheetham T (1998) Diabetes insipidus. Arch Dis Child 79(1):84–89PubMedCrossRefGoogle Scholar
  5. 5.
    De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5–16PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, Walle JV (2011) Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol 185(6):2308–2313PubMedCrossRefGoogle Scholar
  7. 7.
    Dehoorne JL, Raes AM, van Laecke E, Hoebeke P, Vande Walle JG (2006) Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. J Urol 176(2):754–757, discussion 757–758PubMedCrossRefGoogle Scholar
  8. 8.
    Glazener CM, Evans JH (2002) Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 3, CD002112PubMedGoogle Scholar
  9. 9.
    Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, Yeung CK (2004) Nocturnal enuresis: an international evidence based management strategy. J Urol 171(6 Pt 2):2545–2561PubMedCrossRefGoogle Scholar
  10. 10.
    Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167PubMedCrossRefGoogle Scholar
  11. 11.
    Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, Djurhuus JC (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 176(1):314–324PubMedCrossRefGoogle Scholar
  12. 12.
    Norgaard JP, Pedersen EB, Djurhuus JC (1985) Diurnal anti-diuretic-hormone levels in enuretics. J Urol 134(5):1029–1031PubMedGoogle Scholar
  13. 13.
    Osterberg O, Balchen T, Riis A, Senderovitz T (2006) Pharmacokinetics of desmopressin in children and adults using a new oral lyophilisate. Arch Dis Child 91:A31–A34Google Scholar
  14. 14.
    Osterberg O, Savic RM, Karlsson MO, Simonsson US, Norgaard JP, Walle JV, Agerso H (2006) Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol 46(10):1204–1211PubMedCrossRefGoogle Scholar
  15. 15.
    Rittig S, Jensen AR, Jensen KT, Pederson EB (1998) Effect of fod intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (dDAVP) in hydrated normal subject. Clin Endocrinol (Oxf) 48:235–241CrossRefGoogle Scholar
  16. 16.
    Schulman SL, Stokes A, Salzman PM (2001) The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol 166(6):2427–2431PubMedCrossRefGoogle Scholar
  17. 17.
    Theunis M, Van Hoecke E, Paesbrugge S, Hoebeke P, Vande Walle J (2002) Self-image and performance in children with nocturnal enuresis. Eur Urol 41(6):660–667, discussion 667PubMedCrossRefGoogle Scholar
  18. 18.
    Van de Walle J, Van Herzeele C, Raes A (2010) Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf : Int J Med Toxicol Drug Exp 33(4):261–271CrossRefGoogle Scholar
  19. 19.
    van Kerrebroeck PN, Norgaard JP (2009) Desmopressin for the treatment of primary nocturnal enuresis. Pediatr Heal 3(4):317–327Google Scholar
  20. 20.
    Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, Norgaard JP (2006) A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 97(3):603–609PubMedCrossRefGoogle Scholar
  21. 21.
    Vande Walle J, Stockner M, Raes A, Norgaard JP (2007) Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2(3):232–238PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Pauline De Bruyne
    • 1
    Email author
  • Ann De Guchtenaere
    • 2
  • Charlotte Van Herzeele
    • 3
  • Ann Raes
    • 3
  • Jo Dehoorne
    • 3
  • Piet Hoebeke
    • 4
  • Erik Van Laecke
    • 4
  • Johan Vande Walle
    • 3
  1. 1.Department of Pediatrics, Faculty of Medicine and Health SciencesGhent UniversityGhentBelgium
  2. 2.ZeepreventoriumDe HaanBelgium
  3. 3.Department of Pediatric NephrologyGhent University HospitalGhentBelgium
  4. 4.Department of Pediatric UrologyGhent University HospitalGhentBelgium

Personalised recommendations